Your body is a microbial ecosystem; when its balance collapses, FMT aims not to kill a pathogen but to rebuild the whole community.
Antibiotics can save your life, yet they also unsettle the gut's microbial balance — so the aim is precise, justified use and mindful recovery.
Corticosteroids quiet inflammation powerfully, yet they also thin the gut flora and open the door to fungal overgrowth — fiber and care help buffer the cost.
Immunosuppressants calm the immune system, but they also reshape the gut flora and weaken its defense against pathogens — making mindful eating and infection vigilance essential.
Pain-relieving NSAIDs block the very enzyme that also protects the gut lining — so they often strain the small intestine and its barrier without any warning signs.
Because most serotonin is made in the gut, antidepressants influence not only mood but also gut motility and the microbial community — and the relationship runs both ways.
Antifungals tackle the infection, yet they also disturb the mycobiome — the gut's fungal layer — that normally keeps bacterial populations in check through competition.
Chemotherapy targets fast-dividing tumor cells, but it also bruises the equally fast-renewing gut lining and microbiota — so protecting your gut flora is part of supportive care.
Over-the-counter medicines seem harmless, yet antacids, painkillers and laxatives can quietly reshape the gut environment — especially when taken repeatedly over time.
Your gut microbiome begins in the mouth—oral bacteria swallowed every day reach the intestine, where oral dysbiosis can feed inflammation far downstream.
Microplastics are no longer just an ocean problem: detected in human stool, blood and arterial plaque, they unsettle the gut flora and weaken its barrier in animal studies.
The microbiota is inherited along the maternal line, at birth and through breastfeeding, so tending our own gut community is also a living legacy passed to the next generation.
Swallowed tobacco smoke reaches all the way to the gut, lowering microbial diversity and butyrate production and weakening the gut barrier — but quitting sets gradual recovery in motion.
When inflammatory bowel disease doesn't fit neatly into colitis or Crohn's, this profile guides a cautious, combined approach to FMT.
In Crohn's disease the response to FMT is weaker than in colitis, so it stays investigational and shows the most promise in the biologic-naive, ileocolonic subgroup.